Clinical Trials
7 trialsNCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06683846 2025-08-24
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Phase 2 Recruiting
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT03858855 2020-08-04
Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT00003514 2013-07-10
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00004922 2013-06-19
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00423254 2010-08-03
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
Phase 1 Completed